A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00002280
First received: November 2, 1999
Last updated: August 4, 2011
Last verified: August 2011

November 2, 1999
August 4, 2011
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002280 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Children With Acquired Immunodeficiency Syndrome (AIDS) Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine (Retrovir)

The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.

Not Provided
Interventional
Not Provided
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Drug: Didanosine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
November 1994
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Concomitant medications for the treatment of complications of AIDS.
  • CAUTION:
  • Concomitant use of ddI with the following drugs must be done with extreme caution:
  • Other nucleosides (e.g., ganciclovir).
  • Drugs with toxicities similar to those observed with ddI (e.g., phenytoin).
  • Drugs with significant pancreatic toxicities, including many drugs used for treatment of major opportunistic infections.
  • Use of Sulfonamides or intravenous pentamidine for treatment of acute Pneumocystis carinii pneumonia (PCP) requires discontinuation of ddI for a week following treatment of PCP.
  • Caution should also be exercised with patients having intractable diarrhea or patients following a low sodium diet.

Patients must have the following:

- Diagnosis of AIDS. Demonstrated either significant deterioration despite parenteral dosing with zidovudine (AZT) or significant intolerance to AZT.

Signed informed consent by parent or legal guardian. Evaluations every 7-14 days while taking ddI for the first 4 months. Monthly follow-up is required thereafter.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Acute pancreatitis or any history of pancreatitis.
  • Seizures or a history of seizure disorder.
  • Grade I or greater peripheral neuropathy.
  • Preexisting cardiomyopathy.

Concurrent Medication:

Excluded:

  • Zidovudine (AZT).
  • Chemotherapy with cytotoxic agents.
  • AVOID:
  • Those agents that may cause pancreatitis such as:
  • Pentamidine.
  • Sulfonamides.
  • Antituberculosis drugs.
  • Cimetidine.
  • Ranitidine.
  • Corticosteroids.
  • NOTE the cautionary statement in Patient Inclusion Concurrent Medication.

Patients with the following are excluded:

  • Acute pancreatitis or any history of pancreatitis.
  • Seizures or a history of seizure disorder.
  • Grade I or greater peripheral neuropathy.
  • Preexisting cardiomyopathy.

Prior Medication:

Excluded within 15 days of study entry:

  • Any anti-retroviral except zidovudine (AZT).

Required:

  • Zidovudine (AZT).
Both
3 Months to 12 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002280
039C, AI454-904
Not Provided
Study Director, Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP